Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Resatorvid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Resatorvid 1.2 mg/kg/day | EXPERIMENTAL | - |
| Resatorvid 2.4 mg/kg/day | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Resatorvid | DRUG | Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours. |
| Placebo | DRUG | Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours. |
Inclusion Criteria: * Has clinical evidence of infection defined as the presence of a known or probable source of infection requiring the initiation of parenteral antimicrobial therapy. * Must meet at least 3 of the following 4 criteria for SIRS: * A core temperature greater than 38°C or less th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 1 | PHASE2 | Nogapendekin alfa inbakicept |
| Bluejay Diagnostics, Inc. | BJDX | 2 | - | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 3 | - | Undisclosed |
| Spectral AI, Inc. Class A | MDAI | 1 | N/A | Undisclosed |
Resatorvid is an investigational small molecule being studied for the treatment of severe sepsis in adults. It is a Phase 3 drug candidate developed by Takeda Pharmaceutical Company Limited. The drug has been evaluated in a completed clinical trial, but it is not approved and remains in clinical development.
Resatorvid is a small molecule being developed for sepsis. Its molecular target has not been disclosed in the available information, so its specific mechanism of action is not described here. The drug is being studied for its efficacy and safety in adults with severe sepsis.
Resatorvid is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company has conducted a Phase 3 clinical trial of Resatorvid in adults with severe sepsis, which has been completed.
Resatorvid is in Phase 3 clinical development for sepsis. It has completed one Phase 3 trial, but it is not FDA approved and remains investigational. The drug is not currently in any active clinical trials according to the available data.
Resatorvid has been studied in one clinical trial, NCT00143611, titled 'Efficacy & Safety of Resatorvid in Adults With Severe Sepsis.' This was a Phase 3, randomized, double-blind, placebo-controlled study with 277 participants, conducted across multiple countries including the United States, Japan, and European nations. The trial is completed.
Resatorvid is also known as TAK-242, a small molecule developed by Takeda. It has been investigated in a Phase 3 trial for severe sepsis, which was completed. The drug is not approved and remains in clinical development.